353 related articles for article (PubMed ID: 35418687)
1. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
[TBL] [Abstract][Full Text] [Related]
2. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
3. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A; Koch CE; Liu-Lupo Y; Hellinger RD; Kyung T; Abbott KL; Fröse J; Goulet D; Gordon KS; Eidell KP; Leclerc P; Whittaker CA; Larson RC; Muscato AJ; Yates KB; Dubrot J; Doench JG; Regev A; Vander Heiden MG; Maus MV; Manguso RT; Birnbaum ME; Hemann MT
Nat Commun; 2023 Dec; 14(1):8048. PubMed ID: 38052854
[TBL] [Abstract][Full Text] [Related]
4. IFNγR Pathway Mediates CAR T Cell Cytotoxicity Against Solid Tumors.
Cancer Discov; 2022 Jun; 12(6):1408. PubMed ID: 35452074
[TBL] [Abstract][Full Text] [Related]
5. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
[TBL] [Abstract][Full Text] [Related]
8. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
9. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
10. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Watanabe Y; Tsukahara T; Murata K; Hamada S; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Teramoto A; Nakatsugawa M; Yamashita T; Torigoe T
Br J Cancer; 2023 Mar; 128(5):886-895. PubMed ID: 36526673
[TBL] [Abstract][Full Text] [Related]
11. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
12. Gastrodin synergistically increases migration of interleukin-13 receptor α2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study.
Huang S; Bai Y; An Z; Xu C; Zhang C; Wang F; Zhong C; Zhong X
Phytother Res; 2023 Dec; 37(12):5947-5957. PubMed ID: 37748098
[TBL] [Abstract][Full Text] [Related]
13. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
14. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
15. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
16. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells.
Tudor T; Binder ZA; O'Rourke DM
Neurosurg Clin N Am; 2021 Apr; 32(2):249-263. PubMed ID: 33781506
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
19. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
[TBL] [Abstract][Full Text] [Related]
20. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
